Skip to search formSkip to main contentSkip to account menu

Brintellix

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
In July 2015, the US Food and Drug Administration (FDA) published a drug safety communication regarding errors in prescribing and… 
Review
2016
Review
2016
OBJECTIVE: The Objective of this selective EBM review is to determine where or not, “Is Incidence of Nausea Influenced by… 
Highly Cited
2015
Highly Cited
2015
Vortioxetine (Brintellix): a new serotonergic antidepressant. 
2015
2015
* The Food and Drug Administration is warning health care providers about two drugs with similar-sounding brand names: Brintellix… 
2015
2015
Current evidence does not support the routine use of vortioxetine in the treatment of depression. Family physicians most often… 
Highly Cited
2015
Highly Cited
2015
CONTEXT Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2… 
Highly Cited
2015
Highly Cited
2015
BACKGROUND This 8-week, randomized, double-blind, placebo-controlled study, conducted August 2010-May 2012 in the United States… 
Review
2014
Review
2014
Vortioxetine (Brintellix®) is a serotonin (5-HT) transporter inhibitor that also acts on several 5-HT receptors, such as the 5… 
Review
2014
Review
2014
In the final months of 2013, the US Food and Drug Administration approved two new antidepressant formulations. This column…